Treatment of depressed cutaneous scars with gelatin matrix implant: A multicenter study - 12/10/17

Doi : 10.1016/S0190-9622(87)70150-9

Résumé

Twenty-two centers participated in a study to determine the efficacy and safety of gelatin matrix implant (GMI; Fibrel) in the elevation of depressed cutaneous scars. Gelatin matrix implant is an implant consisting of absorbable gelatin powder and ͛-aminocaproic acid, which is reconstituted with the patient's plasma before being injected intradermally beneath the scar. A total of 321 patients were evaluated after a skin sensitivity test; six of the patients. (1.9%) had a positive response. After a skin test with negative results, 27 patients dropped out of the study for unrelated reasons. The remaining 288 patients were treated with the implant (total of 840 scars), many of whom have been followed up for more than 1 year. Preliminary results show that approximately half of the treated scars showed improvement of greater than 65%. The current data suggest that the improvement lasts at least up to 1 year. Adverse reactions to gelatin matrix implant injections were local and transient, and none of the patients developed major hypersensitivity responses to the treatment. The data indicate that intradermal injections of gelatin matrix implant are safe and effective in correcting the depressed scars selected for this study.

Le texte complet de cet article est disponible en PDF.

Participants in the study include: Larry Millikan, M. D., Department of Dermatology, Tulane University, New Orleans, LA; Theodore Rosen, M.D., Department of Dermatology, Baylor College of Medicine, Houston, TX; Gary Monheit, M.D., Department of Dermatology, University of Alabama, Birmingham, AL; Ching Lau, Ph.D., Andover, MA; A. Melvin Alexander, WD., Department of Dermatology, Howard University, Washington, DC; William Baker, M.D., Department of Dermatology, University of Washington, Seattle, WA; Ivan S. Cohen, M.D., Department of Dermatology, Yale University, New Haven, CT; Gerald Davis, M.D., Department of Dermatology, New York Medical College, New York, NY; William Dorner, M.D., Medical Department of Northeast University College of Medicine, Akron, OH; M. L. Elgart, M.D., Department of Dermatology, George Washington University Medical Center, Washington, DC; Edmond Griffin, M.D., Department of Dermatology, Emory University, Atlanta, GA; John V Hugill, M.D., Fort Meyers, FL; Paul Kelly, M.D., Medical Department, University of California School of Medicine, Los Angeles, CA; Albert Lefkovitz, M.D., Department of Dermatology, Mt. Sinai School of Medicine, New York, NY; Bobby P. Lemay, M.D., Department of Otolaryngology, University of Alabama, Birmingham, AL; Michael McClellan, M.D., Department of Dermatology, Providence Medical Center, Media, PA; Harry Mittelman, M.D., Department of Dermatology, Stanford Hospital and Medical Center, Stanford, CA; William L. Poole, M.D., Department of Dermatology, University of Alabama, Birmingham, AL; Michael Reed, M.D., Department of Dermatology, New York University Medical Center, New York, NY; John Stansbury, M.D., Department of Dermatology, University of Minnesota, Minneapolis, MN; George G. Tisdale, M.D., University Hospital, Birmingham, AL; Hubert C. Watkins, M.D., Department of Dermatology, Loma Linda University School of Medicine, Loma Linda, CA; and David Weinberg, M.D., Department of Dermatology, University of California, San Francisco, CA.
Reprint requests to: Dr. Larry Millikan, Department of Dermatology, Tulane University, 1430 Tulane Ave., New Orleans, LA 70112.